• scAAV9 gene therapies can be delivered to, and produce robust transgene expression in, the critically ischemic mouse limb without adverse impact on perfusion recovery or muscle health/function. • Treatment of the ischemic limb with scAAV9–IGF-1 significantly improved muscle size and strength in male and female mice with hindlimb ischemia. • Differences in the efficacy of scAAV9–IGF-1 were observed, with female mice displaying greater improvements in muscle contractile function than male mice. • IGF-1-mediated improvements in muscle function occurred without changes in limb perfusion recovery or capillary density.
1 November 2022 in Journal of the American Heart Association
Background: Peripheral artery disease (PAD) is associated with gastrocnemius muscle abnormalities. However, the biological pathways associated with gastrocnemius muscle dysfunction and their associations with progression of PAD are largely unknown. This study characterized differential gene and microRNA (miRNA) expression in gastrocnemius biopsies from people without PAD compared with those with PAD. Participants with PAD included those with and without PAD progression. Methods and Results: mRNA and miRNA sequencing were performed to identify differentially expressed genes, differentially expressed miRNAs, mRNA‐miRNA interactions, and associated biological pathways for 3 sets of comparisons: (1) PAD progression (n=7) versus non‐PAD (n=7); (2) PAD no progression (n=6) versus non‐PAD; and (3) PAD progression versus PAD no progression. Immunohistochemistry was performed to determine gastrocnemius muscle fiber types and muscle fiber size. Differentially expressed genes and differentially expressed miRNAs were more abundant in the comparison of PAD progression versus non‐PAD compared with PAD with versus without progression. Among the top significant cellular pathways in subjects with PAD progression were muscle contraction or development, transforming growth factor‐beta, growth/differentiation factor, and activin signaling, inflammation, cellular senescence, and notch signaling. Subjects with PAD progression had increased frequency of smaller Type 2a gastrocnemius muscle fibers in exploratory analyses. Conclusions: Humans with PAD progression exhibited greater differences in the number of gene and miRNA expression, biological pathways, and Type 2a muscle fiber size compared with those without PAD. Fewer differences were observed between people with PAD without progression and control patients without PAD. Further study is needed to confirm whether the identified transcripts may serve as potential biomarkers for diagnosis and progression of PAD.
Cardiometabolic diseases, encompassing cardiovascular and metabolic disorders, represent a significant global health challenge, driven in part by the rising prevalence of obesity and type 2 diabetes. Exercise offers profound benefits in mitigating the progression and impact of cardiometabolic diseases by improving glucose homeostasis, body composition, and cardiovascular function. However, gaps remain in our understanding of the molecular mechanisms underlying these benefits and how to optimize exercise prescriptions for cardiometabolic disease. Animal models are indispensable tools for unraveling these mechanisms and translating findings to human health for improved management of these conditions. Rodent exercise models (eg, treadmill running and wheel running) dominate preclinical research, while resistance training models and high-intensity interval training models have gained in popularity in recent years. This review provides a comprehensive evaluation of existing animal models for cardiometabolic disease and exercise, highlighting their strengths, limitations, and translational relevance. We emphasize the critical need for research to support our mechanistic understanding of the multiorgan health benefits for the prevention of cardiometabolic diseases. In addition, we also highlight the need for research applying well-defined exercise interventions with preclinical disease models to provide translational data to guide future clinical applications for patients with cardiometabolic diseases.